# VolitionRx subsidiary acquires Octamer GmbH for $725,000

VolitionRx Limited's subsidiary Belgian Volition SPRL closed on the acquisition of epigenetic reagent company Octamer GmbH for $725,000 (€650,000) in cash and stock. The deal secures supply of key components for Volition's Nu.Q cancer tests.

- Type: Acquisition
- Announced: 2020-01-10
- Where: Belgium
- Value: $725K
- Status: completed
- Products: recombinant nucleosomes, Nu.Q tests for colorectal and prostate cancers
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [VolitionRx Limited](https://endata.com/companies/44440.md) (acquirer)
- [Belgian Volition SPRL](https://endata.com/companies/44441.md) (acquirer)
- [Octamer GmbH](https://endata.com/companies/44442.md) (target)

## Sources

- [proactiveinvestors.com](https://www.proactiveinvestors.com/companies/news/910380/volitionrx-subsidiary-closes-on-725k-acquisition-of-octamer-gmbh-910380.html), 2020-01-10: "This acquisition means that we will be working with one of the world's leading nucleosome experts, Dr Adrian Schomburg."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.